MiR-329-3p inhibited the immunosuppression of tumor cells and enhanced the response of tumor cells to T-cell-induced cytotoxicity through reducing the expression of lysine-specific demethylase 1A (KDM1A, also known as LSD1).Thus, myocyte enhancer factor 2D (MEF2D) demethylation and PD-L1 expression activation were promoted (145). The gene discussed is KDM1A; the disease is neoplasm.